Sort   by:  
 Page size 
UnknownPhase III trial of carboplatin and paclitaxel with or without sorafenib in metastatic melanoma.
Not available
S-EPMC4878104 | biostudies-literature
UnknownPhase Ib/II Study of Pembrolizumab and Pegylated-Interferon Alfa-2b in Advanced Melanoma.
Not available
S-EPMC6286160 | biostudies-literature
UnknownRandomized, Placebo-Controlled, Phase III Trial of Yeast-Derived Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) Versus Peptide Vaccination Versus GM-CSF Plus Peptide Vaccination Versus Placebo in Patients With No Evidence of Disease After Complete Surgical Resection of Locally Advanced and/or Stage IV Melanoma: A Trial of the Eastern Cooperative Oncology Group-American College of Radiology Imaging Network Cancer Research Group (E4697).
Not available
S-EPMC4669592 | biostudies-literature
UnknownNivolumab Plus Ipilimumab in Patients With Advanced Melanoma: Updated Survival, Response, and Safety Data in a Phase I Dose-Escalation Study.
Not available
S-EPMC5946731 | biostudies-literature
UnknownSouthwest Oncology Group S0008: a phase III trial of high-dose interferon Alfa-2b versus cisplatin, vinblastine, and dacarbazine, plus interleukin-2 and interferon in patients with high-risk melanoma--an intergroup study of cancer and leukemia Group B, Children's Oncology Group, Eastern Cooperative Oncology Group, and Southwest Oncology Group.
Not available
S-EPMC4226807 | biostudies-literature
UnknownPhase III Randomized Study of 4 Weeks of High-Dose Interferon-α-2b in Stage T2bNO, T3a-bNO, T4a-bNO, and T1-4N1a-2a (microscopic) Melanoma: A Trial of the Eastern Cooperative Oncology Group-American College of Radiology Imaging Network Cancer Research Group (E1697).
Not available
S-EPMC5455684 | biostudies-literature
UnknownPhase III randomized clinical trial comparing tremelimumab with standard-of-care chemotherapy in patients with advanced melanoma.
Not available
S-EPMC4878048 | biostudies-literature
UnknownLonger Follow-Up Confirms Relapse-Free Survival Benefit With Adjuvant Dabrafenib Plus Trametinib in Patients With Resected BRAF V600-Mutant Stage III Melanoma.
Not available
S-EPMC6286159 | biostudies-literature
UnknownCombination of Itacitinib or Parsaclisib with Pembrolizumab in Patients with Advanced Solid Tumors: A Phase I Study.
Not available
S-EPMC10729644 | biostudies-literature
UnknownLigand-independent EPHA2 signaling drives the adoption of a targeted therapy-mediated metastatic melanoma phenotype.
Not available
S-EPMC4355213 | biostudies-literature
Sort   by:  
 Page size